These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 39013412

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
    Tan Q, Akindehin SE, Orsso CE, Waldner RC, DiMarchi RD, Müller TD, Haqq AM.
    Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA, Quast DR, Wefers J, Pfeiffer AFH.
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
    Leuthardt AS, Boyle CN, Raun K, Lutz TA, John LM, Le Foll C.
    Eur J Pharmacol; 2023 Sep 15; 955():175912. PubMed ID: 37454968
    [Abstract] [Full Text] [Related]

  • 33. [A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists].
    Scheen A.
    Rev Med Liege; 2024 Sep 15; 79(9):605-612. PubMed ID: 39262368
    [Abstract] [Full Text] [Related]

  • 34. Incretin actions beyond the pancreas: lessons from knockout mice.
    Yabe D, Seino Y.
    Curr Opin Pharmacol; 2013 Dec 15; 13(6):946-53. PubMed ID: 24095602
    [Abstract] [Full Text] [Related]

  • 35. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B, Gelfanov VM, El K, Chen A, Rohlfs R, DuBois B, Kruse Hansen AM, Perez-Tilve D, Knerr PJ, D'Alessio D, Campbell JE, Douros JD, Finan B.
    Mol Metab; 2022 Dec 15; 66():101638. PubMed ID: 36400403
    [Abstract] [Full Text] [Related]

  • 36. Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.
    Folli F, Finzi G, Manfrini R, Galli A, Casiraghi F, Centofanti L, Berra C, Fiorina P, Davalli A, La Rosa S, Perego C, Higgins PB.
    Am J Physiol Endocrinol Metab; 2023 Nov 01; 325(5):E595-E609. PubMed ID: 37729025
    [Abstract] [Full Text] [Related]

  • 37. Cardiovascular biology of the GIP receptor.
    Greenwell AA, Chahade JJ, Ussher JR.
    Peptides; 2020 Mar 01; 125():170228. PubMed ID: 31812593
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Genetic determinants of circulating GIP and GLP-1 concentrations.
    Almgren P, Lindqvist A, Krus U, Hakaste L, Ottosson-Laakso E, Asplund O, Sonestedt E, Prasad RB, Laurila E, Orho-Melander M, Melander O, Tuomi T, Holst JJ, Nilsson PM, Wierup N, Groop L, Ahlqvist E.
    JCI Insight; 2017 Nov 02; 2(21):. PubMed ID: 29093273
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.